<DOC>
	<DOCNO>NCT01573910</DOCNO>
	<brief_summary>The purpose study evaluate Moxifloxacin 0.5 % relative Ofloxacin 0.3 % treatment bacterial conjunctivitis Chinese patient .</brief_summary>
	<brief_title>An Evaluation Safety Efficacy Moxifloxacin Ophthalmic Solution 0.5 % ( ( VIGAMOXÂ® ) Versus Ofloxacin Ophthalmic Solution 0.3 % Treatment Bacterial Conjunctivitis Chinese Patients</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Bacterial</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Chinese . Diagnosis bacterial conjunctivitis base clinical observation . Understand sign approve informed consent . Legally authorized representative provide inform consent patient le 18 year old and/or incapable understanding informed consent . Willing complete require study procedure visit . Other protocoldefined inclusion criterion may apply . Women pregnant , lactating , planning pregnancy . Only 1 sight eye vision correctable 0.6 logMAR well either eye . Planned contact lens wear course study . Signs symptoms bacterial conjunctivitis longer 4 day prior Screening ( Day 1 ) . Suspected fungal , viral , Acanthamoeba infection . Any systemic ocular disease disorder , complicate factor structural abnormality would negatively affect conduct outcome study . History recent surgery . Presence concomitant systemic viral infection . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Bacterial conjunctivitis</keyword>
	<keyword>Anti-infective</keyword>
	<keyword>Antibiotics</keyword>
</DOC>